Market Cap 10.71B P/E - EPS this Y -13.10% Ern Qtrly Grth -
Income -615.11M Forward P/E 4.51 EPS next Y 490.10% 50D Avg Chg -23.00%
Sales 919.45M PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 10.30 EPS next 5Y - 52W High Chg -56.00%
Recommedations 2.20 Quick Ratio 1.74 Shares Outstanding 74.09M 52W Low Chg 257.00%
Insider Own 0.55% ROA -25.53% Shares Float 69.28M Beta 1.53
Inst Own 58.06% ROE -121.19% Shares Shorted/Prior 4.45M/4.29M Price 144.55
Gross Margin -43.87% Profit Margin -66.90% Avg. Volume 3,709,038 Target Price 288.25
Oper. Margin -65.23% Earnings Aug 9 Volume 2,822,142 Change 3.13%

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

NVAX Chatroom

User Image Lel0uche_Vi_Brittania Posted - 4 minutes ago

$NVAX my 85 shares are happy today

User Image karlnash Posted - 6 minutes ago

$NVAX SK Bioscience Receives EU-GMP Certification for COVID-19 Vaccine Production Plant, Making it Korea’s First "The approved production plant is located at the Andong Plant L House and is used for producing Novavax’s NVX-CoV2373 and AstraZeneca’s AZD1222. The EU-GMP will provide SK bioscience access to exporting vaccines to the EU market, expanding the possible CMO and CDMO deals. SK bioscience said that L House consists of advanced technology-based manufacturing facilities and R&D personnel optimized to carry out vaccine production, including activities such as cell cultivation, bacterial cultivation, gene recombination, and protein conjugation so that even the newest vaccines can immediately enter mass production." https://geneonline.news/en/sk-bioscience-receives-eu-gmp-certification-for-covid-19-vaccine-production-plant-making-it-koreas-first/

User Image From_Stately_Wood_Manor Posted - 10 minutes ago

$NVAX Risky? Risky? You can't handle risky. Only the strong are long. NVAXERs love the smell of risk in the morning. Risk? Go ahead. Make our day. https://www.fool.com/investing/2021/05/17/5-risky-stocks-with-138-to-216-upside-wall-street/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

User Image jamstah Posted - 19 minutes ago

$NVAX HHS/ OWS contract published. Heavily redacted but a few snippets of information that might have been missed before: - Assumes a vaccine manufacturing cost of $4 per dose for 100m doses - Optional 560m doses can be ordered under the contract - IP rights maintained - Original forecast was to deliver 100m doses in December 2020 for the 5ug dose! Extremely behind schedule to say the least https://www.hhs.gov/sites/default/files/novavax-covid-19-vaccine-contract.pdf

User Image CalvinBakers Posted - 34 minutes ago

The 12-month forecast for Novavax Inc($NVAX) is out now – Wall Street Facts https://wallstreetfacts.com/2021/05/17/the-12-month-forecast-for-novavax-incnvax-is-out-now-2/

User Image LivStocksMkt Posted - 35 minutes ago

$IBIO Vaccines Market Size 2021 | Is Projected to Reach USD $104.87 Billion by 2027, Exhibiting a CAGR of 10.7 % $PFE $NVAX $MRNA

User Image ChartMill Posted - 44 minutes ago

Measured over the past 5 years, $NVAX shows a very strong growth in Revenue: 126.71% on average per year. https://www.chartmill.com/stock/quote/NVAX/fundamental-analysis?key=a723be0a-acee-47cf-b597-162b253fec2c&utm_source=stocktwits&utm_medium=FA&utm_content=NVAX&utm_campaign=social_tracking

User Image melaudrey157 Posted - 46 minutes ago

$NVAX (Pipeline) Pediatric Respiratory Syncytial Virus (Rsv) Prophylactics Market Growing Demand with Innovative Ideas Adopted by Key Players – AstraZeneca and Novavax https://manometcurrent.com/pediatric-respiratory-syncytial-virus-rsv-prophylactics-market-growing-demand-with-innovative-ideas-adopted-by-key-players-astrazeneca-and-novavax/

User Image joedoe007 Posted - 1 hour ago

$NVAX If we get a sharp dip tomorrow, i will sell my nvax put options. If we get $151+ again (which is highly doubtful), i may think of adding to my exisiting PUT options.

User Image Long_Hold Posted - 1 hour ago

$NVAX Does anyone here has a word about SK bioscience target mfg throughput per month ? assuming $Nvax can still sell all it can produce, this info is going to be key to readjust the TP. My hunch is telling me SK bioscience will be producing mainly for EU and middle east rich countries . If they manage to get us an extra 2 billion revenue, ( 30 million doses/month) @40% license fee, we should comfortably add an extra $140 on TP, this really makes me think tge $650 by EOY is not that far fetched after all !!

User Image ikesmail Posted - 1 hour ago

$NVAX and the US market is important, but the opportunity and necessity is internationally RIGHT NOW..... my hope is that the US in good faith orders more Novavax for the US market for 2022 considering all their efforts, effectiveness, and safety. Plus it gives them another GREAT vaccine that doesn't cost as much (total cost of storage and distribution is very high with RNA vaccines). let's go!

User Image Hodl_life Posted - 1 hour ago

$NVAX longs i bought all i can, avg down from $200 to $180 as of now, considering i HODL(asmy name says) whats all ur PT by EOY ? be logical i have 15% of my portfolio here, thnx !!!

User Image ikesmail Posted - 1 hour ago

$NVAX My hope is $175 by EOW with positive news on Friday to as high as $200..... that would be a perfect spot to blast with news next week on trial and then EU deal signed..... If the data results are great and then EU deal occur in a 2-5 day time period this stock is going to SOAR... but I'd take $160 as well by the end of week and still in good position....

User Image CalvinBakers Posted - 1 hour ago

The 12-month forecast for Novavax Inc($NVAX) is out now – Wall Street Facts https://wallstreetfacts.com/2021/05/17/the-12-month-forecast-for-novavax-incnvax-is-out-now-2/

User Image Lel0uche_Vi_Brittania Posted - 1 hour ago

$NVAX where can u vote on sompensation

User Image webman9113 Posted - 1 hour ago

Added to my $NVAX position at 140.77. Now let’s see if price can beat the SMA200 overhead.

User Image jamstah Posted - 2 hours ago

$NVAX I want to highlight a few risks in US trial design vs the UK trial 1st: minorities are a bigger percentage in the US trial ~40%+ vs. single digits in the UK. The UK pre print data had lower efficacy for minorities (76%) but the sample size was small with a large interval range. Potential impact:possibly negative 2nd: many participants took antibody tests which may change behavior/ lead to higher dropouts in placebo arm. Potential impact: even smaller placebo arm, may need to combine data for placebo across UK and US. 3rd: variants. While the UK variant was not a big proportion of cases when trial kicked off by the end of April, CDC data shows it increased to 60% of all cases. Potential impact: positive but decreases if case accrual is later vs earlier. 4th: more high risk individuals. Potential impact: unknown but provided recruitment and dropouts were similar across both arms - then it would just mean a faster case accrual rate

User Image ay8888 Posted - 2 hours ago

$NVAX in case many of you guys are so focused on NVAX price, the reason why we retraced from 150 to 145 is the broad market was red red red.

User Image HardToLove Posted - 2 hours ago

$NVAX Opening comments (~noon though) https://bit.ly/2S381ZU. Spread stayed @ $140.29/$151.57 (LOD @ open, HOD 10:36), 8.04%. Lucky today, my "Will end with good day" proved out. Close was MM's closing BUY of 71,305 at $144.55 ($10,307,137.75), +3.04% off $140.29 open & +3.13% off $140.16 prior close. Volume, through 16:57, was ~2.825MM, marginally up from yesterday's (with all AH included) ~2.811MM. We can call it flat until all AH is in but I think it will still be close. That's not bad. Only third consecutive green candle day and we spent all day, from 9:31 EDT onward, above the $140.42 gap bottom marked by the lower horizontal red line. Another close above tomorrow would be a good sign. Would want to see volume up too. Need to close the gap marked with the new lower right green lines, $148.60/$158.01. Options expiration Friday a day closer, may be tough? Especially if tomorrow is what one-minute chart (later post) suggests. NVAX caught a break today.

User Image ay8888 Posted - 2 hours ago

$NVAX The last press release by Novavax was May 10 earnings. I’m really hoping the are busy preparing for the Vaccine summit and we have PR next 3 days

User Image Catfish123 Posted - 2 hours ago

$NVAX I voted NO for the stock compensation. I figure I was wasting my time because the Executives will decide to increase available shares and dilute the outstanding stocks. They will say they need operational money and turn around and give out incentives. They always win.

User Image Glackattack Posted - 2 hours ago

$NVAX How many fools get back on here and complain about me blocking them? I'm sure there are quite a few. I don't see their complaints because I've blocked them. Keep stalking me losers. Get a life.

User Image CalvinBakers Posted - 2 hours ago

The 12-month forecast for Novavax Inc($NVAX) is out now – Wall Street Facts https://wallstreetfacts.com/2021/05/17/the-12-month-forecast-for-novavax-incnvax-is-out-now-2/

User Image ChartMill Posted - 2 hours ago

$NVAX was analyzed by 5 analysts. The buy consensus is at 92%. So analysts seem to be very confident about $NVAX. https://www.chartmill.com/stock/analyzer/stock/NVAX?view=analyst-ratings&utm_source=stocktwits&utm_medium=ANALYST&utm_content=NVAX&utm_campaign=social_tracking

User Image tradersgraphics Posted - 2 hours ago

$NVAX NVAX 2021-05-18 Options Analysis Video: https://www.youtube.com/watch?v=-zhCVwovrjQ

User Image Stoneman11 Posted - 2 hours ago

$RAIL great call with this one @zmanx only down 40% here too lmaoooo $NVAX $CLVS $SOS the bag king z man lmao ass clown

User Image LivStocksMkt Posted - 3 hours ago

$IBIO was $55 in 2011. Not a little Covid19 Vaccine stock. runs with the big boys like Pfizer $PFE Moderna $MRNA and Novavax $NVAX imo.

User Image Will_I_AM4 Posted - 3 hours ago

$NVAX It has been a tough few months for medical and tech markets but I think some of these are going to bounce back hard very soon! $OCGN $EYES https://youtu.be/jxJpL7bRGgw

User Image ProfessorDman1 Posted - 3 hours ago

$NLSP today was Green Day on news ( locked and loaded ) 100%-300%+ potential from this level . Do some DD you will see it. Same thing I have analyzed it on $NVAX under $5 last year and ran $331 ! Many other bottom bios ideas.. NLSP has no debt 💸 cash on hand with multiple patents/catalyst ongoing ! $12 PT by analyst more news in making for NLSP

User Image BiotechMike141 Posted - 3 hours ago

$NVAX Wish we could have stayed above $150. Hopefully in the next few days 🙏🙏

Analyst Ratings
Cantor Fitzgerald Overweight May 12, 21
HC Wainwright & Co. Buy May 12, 21
JP Morgan Neutral May 12, 21
HC Wainwright & Co. Buy Mar 12, 21
B. Riley FBR Buy Feb 18, 21
Cantor Fitzgerald Overweight Feb 5, 21
B. Riley FBR Buy Feb 1, 21
Jefferies Buy Dec 14, 20
HC Wainwright & Co. Buy Nov 17, 20
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own
Glenn Gregory M President, R&.. President, R&D Apr 19, 9:24 PM Option 61.73 10,531 650,079 7,630
MCMANUS MICHAEL A JR Director Director Mar 23, 5:33 PM Sell 220.99 4,000 883,960 5,951
Trizzino John EVP, Chief Co.. EVP, Chief Commercial Officer Mar 9, 7:38 PM Option 21.38 3,404 72,778 670
Trizzino John EVP, Chief Co.. EVP, Chief Commercial Officer Mar 9, 7:38 PM Sell 163.31 3,211 524,388 287
Herrmann John A III EVP, Chief Le.. EVP, Chief Legal Officer Feb 3, 5:37 PM Option 26.71 15,022 401,238 15,297
Herrmann John A III EVP, Chief Le.. EVP, Chief Legal Officer Feb 3, 5:37 PM Sell 241.28 15,022 3,624,508 275
Trizzino John EVP, CMO and.. EVP, CMO and CBO Jan 7, 7:08 PM Option 23.25 13,756 319,827 1,436
Trizzino John EVP, CMO and.. EVP, CMO and CBO Jan 7, 7:08 PM Sell 114.35 17,913 2,048,352 287
Erck Stanley C President and.. President and CEO Nov 18, 6:09 PM Option 32.7 52,317 1,710,766 72,811
Erck Stanley C President and.. President and CEO Nov 18, 6:09 PM Sell 90.33 52,316 4,725,704 20,495
Trizzino John EVP, CBO and.. EVP, CBO and CFO Oct 1, 5:40 PM Sell 111.32 2,250 250,470 5,087
Erck Stanley C President and.. President and CEO Oct 1, 5:39 PM Sell 111.71 12,233 1,366,548 20,494
Herrmann John A III EVP, Chief Le.. EVP, Chief Legal Officer Sep 30, 9:30 PM Option 5.95 24,750 147,262 43,054
Herrmann John A III EVP, Chief Le.. EVP, Chief Legal Officer Sep 30, 9:30 PM Sell 110.91 42,779 4,744,618 275
Glenn Gregory M President, R&.. President, R&D Sep 30, 9:29 PM Option 5.95 25,000 148,750 46,510
Glenn Gregory M President, R&.. President, R&D Sep 30, 9:29 PM Sell 110.91 44,949 4,985,295 1,561
Trizzino John EVP, CBO and.. EVP, CBO and CFO Sep 30, 9:28 PM Option 5.95 29,600 176,120 53,008
Trizzino John EVP, CBO and.. EVP, CBO and CFO Sep 30, 9:28 PM Sell 110.86 43,321 4,802,567 7,337
Erck Stanley C President and.. President and CEO Sep 30, 9:27 PM Option 5.95 50,000 297,500 74,606
Erck Stanley C President and.. President and CEO Sep 30, 9:27 PM Sell 110.91 29,112 3,228,813 32,727